NCT06766786|Completed
Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation
Perioperative Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation Patients
Loading search results
Perioperative Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation Patients
Sponsor study identifier
observational
40
1 country
1
Study Start
January 2, 2008
Actual (reported)Primary Completion
February 20, 2020
Actual (reported)Study Completion
February 20, 2020
Actual (reported)Magnesium is essential in human physiology. Simultaneous pancreas-kidney (SPK) transplant recipients frequently experience hypomagnesemia. The effects of hypomagnesaemia are harmful. This observational study assessed intraoperative magnesium supplementation's utility in patients undergoing SPK transplantation. Perioperative hemodynamics were monitored. Postoperative serum magnesium was monitored at 12 hours and 48 hours.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 20, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2, 2008
Actual (reported)February 20, 2020
Actual (reported)February 20, 2020
Actual (reported)January 5, 2025
Actual (reported)January 9, 2025
Actual (reported)Serum magnesium levels.
Serum magnesium levels after surgery at 12 and 48 hours.
48 hours
Perioperative cardiovascular incidents.
Incidence rate of intraoperative and postoperative dysrhythmia events for each patient.
48 hours
Postoperative neurological incidents.
48 hours
Adult patients with diabetes mellitus and chronic pancreas-kidney failure who require insulin and hemodialysis therapy. Intravenous magnesium supplementation was given intraoperatively to consenting patients receiving simultaneous pancreas-kidney (SPK) transplantation.
Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
Cohort population of consecutive adult pancreatic-kidney failure patients on regular insulin and hemodialysis therapy and consenting to simultaneous pancreas-kidney (SPK) transplantation.
Central Manchester University Hospital
Manchester, Manchester, M13 9WU, United Kingdom
Bamgbade OA. Intraoperative magnesium supplementation improves gynecology major surgery perioperative outcome. J Clin Anesth. 2018 Feb;44:21. doi: 10.1016/j.jclinane.2017.10.019. No abstract available.
Olumuyiwa Bamgbade, MD, FRCPC
Salem Anaesthesia Pain Clinic
40 participants (actual enrollment reported by the registry).
First Submitted
January 5, 2025
First Posted
January 9, 2025
Study Start
January 2, 2008
Actual (reported)Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Contact the study team to confirm eligibility.
Primary Completion
February 20, 2020
Actual (reported)Study Completion
February 20, 2020
Actual (reported)Last Updated
January 9, 2025
Record last verified: 2025-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: